Comparing GH Research (NASDAQ:GHRS) and RegeneRx Biopharmaceuticals (OTCMKTS:RGRX)

GH Research (NASDAQ:GHRS) and RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Risk & Volatility

GH Research has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, RegeneRx Biopharmaceuticals has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500.

Profitability

This table compares GH Research and RegeneRx Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-15.48%	-15.01%
RegeneRx Biopharmaceuticals	N/A	N/A	N/A

Earnings & Valuation

This table compares GH Research and RegeneRx Biopharmaceuticals’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$35.59 million	($0.68)	-15.44
RegeneRx Biopharmaceuticals	$80,000.00	0.03	-$1.73 million	N/A	N/A

RegeneRx Biopharmaceuticals has higher revenue and earnings than GH Research.

Analyst Recommendations

This is a summary of recent ratings for GH Research and RegeneRx Biopharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	0	0	2	0	3.00
RegeneRx Biopharmaceuticals	0	0	0	0	N/A

GH Research currently has a consensus target price of $39.50, suggesting a potential upside of 276.19%. Given GH Research’s higher probable upside, analysts plainly believe GH Research is more favorable than RegeneRx Biopharmaceuticals.

Insider & Institutional Ownership

56.9% of GH Research shares are held by institutional investors. 41.6% of GH Research shares are held by company insiders. Comparatively, 12.6% of RegeneRx Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

RegeneRx Biopharmaceuticals beats GH Research on 5 of the 9 factors compared between the two stocks.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

About RegeneRx Biopharmaceuticals

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.